Development of an enzymatic pretargeting strategy for dual-modality imaging.
Knight JC., Mosley M., Stratford MRL., Uyeda HT., Benink HA., Cong M., Fan F., Faulkner S., Cornelissen B.
A pretargeted imaging strategy based on the HaloTag dehalogenase enzyme is described. Here, a HaloTag-Trastuzumab conjugate has been used as the primary agent targeting HER2 expression, and three new radiolabelled HaloTag ligands have been used as secondary agents, two of which offer dual-modality (SPECT/optical) imaging capability.